Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.700
Open
4.710
VWAP
5.14
Vol
1.20M
Mkt Cap
8.99M
Low
4.620
Amount
6.16M
EV/EBITDA(TTM)
--
Total Shares
2.27M
EV
4.10M
EV/OCF(TTM)
--
P/S(TTM)
--
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
--
--
-0.013
-99.68%
--
--
-0.013
-99.66%
--
--
-0.013
-99.41%
Estimates Revision
The market is revising No Change the revenue expectations for NuCana plc (NCNA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -28.42%.
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-28.42%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for NuCana PLC (NCNA.O) is -85.96, compared to its 5-year average forward P/E of -3.37. For a more detailed relative valuation and DCF analysis to assess NuCana PLC 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.37
Current PE
-85.96
Overvalued PE
7.48
Undervalued PE
-14.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.54
Undervalued EV/EBITDA
-1.01
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.26
Current PS
0.00
Overvalued PS
12.31
Undervalued PS
-7.80
Financials
Annual
Quarterly
FY2025Q1
YoY :
-66.62%
-2.79M
Operating Profit
FY2025Q1
YoY :
-63.83%
-2.47M
Net Income after Tax
FY2025Q1
YoY :
-99.37%
-0.02
EPS - Diluted
FY2025Q1
YoY :
-46.58%
-3.12M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NCNA News & Events
Events Timeline
2025-07-21 (ET)
2025-07-21
08:18:21
NuCana cancels all outstanding Series A Warrants
2025-05-06 (ET)
2025-05-06
08:36:24
NuCana prices 10.8M ADSs at 64.54c in registered direct offering
2025-04-24 (ET)
2025-04-24
06:16:05
NuCana files to sell 16.05M American Depositary Shares
Sign Up For More Events
Sign Up For More Events
News
9.0
08-10TipRanksUpcoming Stock Splits This Week (August 11 to August 15) – Stay Invested
8.5
08-01NewsfilterNuCana Announces ADS Ratio Change
8.5
07-10BenzingaWhy WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
FAQ
What is NuCana PLC (NCNA) stock price today?
The current price of NCNA is 4.71 USD — it has increased 5.37 % in the last trading day.
What is NuCana PLC (NCNA)'s business?
What is the price predicton of NCNA Stock?
What is NuCana PLC (NCNA)'s revenue for the last quarter?
What is NuCana PLC (NCNA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for NuCana PLC (NCNA)'s fundamentals?
How many employees does NuCana PLC (NCNA). have?